Opportunities in the Next Generation Cancer Diagnostics Market include leveraging advancements in genomic and proteomic ...
Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...
"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...
Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...
With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.
Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests ...
A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing ...
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...
Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results